AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Moderna covid 19 vaccine production capacity11/30/2023 ![]() Support was provided for mapping COVID-19 vaccine manufacturing capacity. There was also an ability to invest in production to address other potential bottlenecks, including vials, needles and syringes, and cold storage capacity. This included investments in vaccine manufacturers to foster increased production of COVID-19 vaccines in low- and middle-income countries, with production allocated for emerging markets. IFC’s $4 billion Global Health Platform had supported private companies in providing health products and services – including vaccines to developing countries. This financing could be utilized by countries to make payments to COVAX, which included the purchase of additional doses beyond the COVAX-provided 20% as countries aimed for higher coverage levels. The World Bank Group worked in global solidarity with COVAX, WHO, UNICEF and other partners at global and country levels to aid IDA and IBRD countries. ![]() All eligible Bank client countries (IBRD/IDA) had the opportunity to access the vaccine financing within their existing lending envelopes for IDA countries and exposure limits for IBRD. Such a commitment offered an incentive for vaccine manufacturers to provide for developing economies at affordable prices. The World Bank had swiftly mobilized vaccine financing with the aim to aid affordable and equitable vaccine acquisition and deployment, and to indicate to potential suppliers that Bank financing was accessible to its clients. COVID vaccines: Why we must succeed in every country 8th Meeting of the MLTF on COVID-19, 3rd High-Level Consultations with Vaccine Manufacturers World Bank Group’s $157 Billion Pandemic Surge is Largest Crisis Response in its History COVAX and World Bank to Accelerate Vaccine Access for Developing Countries World Bank Board Approves New Fund for Pandemic Prevention, Preparedness and Response (PPR) ![]() Responding to COVID-19 and Rebuilding Better (brochure) Operational Response to COVID-19 - Projects List How we are helping countries with COVID-19 Remarks by World Bank Group President David Malpass at the G20 Joint Finance, Health Ministerial World Bank Group COVID-19 Crisis Response Operational Update: Delivering on the WBG Twin Goals in an Era of Compounding Crises ![]() Accelerating COVID-19 Vaccine Deployment By February 2020, Moderna had begun manufacturing samples of a synthetic mRNA vaccine for the National Institutes of Health to use in animal studies, with the hopes they could be used in first-stage safety tests in people within three months, The Associated Press reported at the time.- Remarks by World Bank Group President David Malpass at the Virtual COVID-19 Global Action Plan Foreign Ministerial Meeting The virus’ sequence was released in mid-January 2020. The World Health Organization formally declared COVID-19 a pandemic on March 11, 2020, but cases had been rapidly mounting for weeks prior. “In the first quarter of 2021 alone, we shipped over 100 million doses and are now on a trajectory to produce 1 billion doses for this year,” “In 2019, we made fewer than 100,000 doses of vaccine,” he told the group. In a November 2021 interview with the American Heart Association, Bancel described a similar timeline, telling the organization that Moderna made less than 100,000 doses of any vaccine in all of 2019.Īnd in an August 2021 interview with Pictet Asset Management, a global financial institution, Bancel reiterated similar comments. Previous interviews with Bancel in which he makes nearly identical remarks also make clear that he’s comparing 2019 doses of any kind of vaccine with the upgraded capacity put into place once the virus began rapidly spreading in early 2020. Social media users sharing this clip to suggest Bancel was admitting to predicting the pandemic, and preliminarily producing vaccines, ignore the fact that he does not specify what kind of doses he’s discussing when he mentions 2019 production. And I remember walking into the office of my manufacturing and I say, ‘How about we make a billion dose next year?’ And they look at me a bit funny and say, ‘What?’ And I say, ‘Yeah we need to make a billion dose next year, there’s going to be a pandemic.’” As Seth knows, when the pandemic happened, Moderna had made 100,000 dose in 2019 for the whole year. To this, Bancel responds: “So the great news versus 2020, where we are today is that we have manufacturing capacity. How is development, adoption and scaling of the vaccine going when it comes to different variants and sub-variants?” In the 58-second clip posted to social media, the moderator asks: “Let’s talk about vaccine development because we’ve heard how it happened obviously with COVID-19, starting from 2022 and how extraordinary the process was also in terms of the speed.
0 Comments
Read More
Leave a Reply. |